SAN FRANCISCO — Results from three trials evaluating Abbott Vascular's (Abbott Park, Ill.) fully absorbable stent showed non-inferiority of the device over the firm's own Xience drug-eluting stent (DES). However the data did little to provide a home run for the effectiveness of Absorb, which has yet to gain FDA approval, when the stent was compared to DES technology. Read More
